Comparative Pharmacology
Head-to-head clinical analysis: DEFERASIROX versus JADENU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERASIROX versus JADENU.
DEFERASIROX vs JADENU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron burden in transfusion-dependent patients.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces.
Initial: 20 mg/kg orally once daily. Maintenance: 20-40 mg/kg orally once daily (maximum 40 mg/kg/day).
30 mg/kg once daily orally, up to a maximum of 60 mg/kg/day, for iron chelation in patients with thalassemia or other chronic iron overload; dose should be adjusted based on serum ferritin levels and therapeutic response.
None Documented
None Documented
Clinical Note
moderateDeferasirox + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateDeferasirox + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox."
Clinical Note
moderateCarprofen + Deferasirox
Terminal elimination half-life is 8–16 hours in patients with transfusional iron overload; higher iron burden prolongs half-life due to enterohepatic recirculation.
Terminal elimination half-life is 8-16 hours (mean ~12 h) in patients with transfusional iron overload, allowing once-daily dosing.
Primarily fecal (84%) as unchanged drug via biliary excretion; renal excretion accounts for approximately 8% as unchanged drug and metabolites.
Primarily fecal (hepatobiliary) ~75-90% as unchanged drug and iron complex; renal excretion of deferasirox is minimal (<5% unchanged).
Category C
Category C
Iron Chelator
Iron Chelator
"The risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox."